Search results for "PROLIFERATOR-ACTIVATED RECEPTORS"

showing 6 items of 16 documents

Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.

2021

Abstract Natural products and synthetic analogs have drawn much attention as potential therapeutical drugs to treat metabolic syndrome. We reviewed the underlying mechanisms of 32 natural products and analogs with potential pharmacological effects in vitro, and especially in rodent models and/or patients, that usually act on the PPAR pathway, along with other molecular targets. Recent outstanding total syntheses or semisyntheses of these lead compounds are stated. In general, they can activate the transcriptional activity of PPARα, PPARγ, PPARα/γ, PPARβ/δ, PPARα/δ, PPARγ/δ and panPPAR as weak, partial agonists or selective PPARγ modulators (SPPARγM), which may be useful for managing obesity…

Peroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptorPharmacologyResveratrol01 natural sciences03 medical and health scienceschemistry.chemical_compoundStructure-Activity RelationshipBerberineDrug DiscoverymedicineAnimalsHumansReceptor030304 developmental biologyPharmacologychemistry.chemical_classificationMetabolic Syndrome0303 health sciencesBiological ProductsDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOrganic ChemistryGeneral MedicinePPAR Pathwaymedicine.disease0104 chemical sciencesCurcuminQuercetinDyslipidemiaEuropean journal of medicinal chemistry
researchProduct

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.

2022

Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists (“glitazones”) are no longer prioritized due to their effects on heart failure. However, the association between these drugs and innovative therapies could be a valuable tool to attenuate the risk factors of the metabolic syndrome. Glitazones are used for the treatment of diabetes and associated comorbidities. There is substantial scientific evidence demonstrating the effect of glitazones at a cardiometabolic level, as well as on hematological and neurological pathologies that po…

RosiglitazoneDiabetes Mellitus Type 2PioglitazonePeroxisome Proliferator-Activated ReceptorsHumansHypoglycemic AgentsThiazolidinedionescardiovascular risk metabolic syndrome pioglitazone type 2 diabetes mellitusGeneral MedicineMedicina (Kaunas, Lithuania)
researchProduct

Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance

2008

Background Exercise practitioners often take vitamin C supplements because intense muscular contractile activity can result in oxidative stress, as indicated by altered muscle and blood glutathione concentrations and increases in protein, DNA, and lipid peroxidation. There is, however, considerable debate regarding the beneficial health effects of vitamin C supplementation. Objective This study was designed to study the effect of vitamin C on training efficiency in rats and in humans. Design The human study was double-blind and randomized. Fourteen men (27-36 y old) were trained for 8 wk. Five of the men were supplemented daily with an oral dose of 1 g vitamin C. In the animal study, 24 mal…

VitaminAdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentPeroxisome Proliferator-Activated ReceptorsMedicine (miscellaneous)Administration OralAscorbic AcidBiologymedicine.disease_causeAntioxidantsLipid peroxidationMitochondrial Proteinschemistry.chemical_compoundOxygen ConsumptionDouble-Blind MethodInternal medicinemedicineAnimalsHumansRats Wistarchemistry.chemical_classificationNutrition and DieteticsCross-Over StudiesVitamin CNuclear Respiratory Factor 1Glutathione peroxidaseAscorbic acidAdaptation PhysiologicalMitochondria MuscleRatsDNA-Binding ProteinsOxidative StressEndocrinologychemistryMitochondrial biogenesisDietary SupplementsPhysical EnduranceReactive Oxygen SpeciesOxidative stressTranscription Factors
researchProduct

Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.

2004

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and peroxisome proliferator-activated receptor alpha activators (fibrates) are the backbone of pharmacologic hypercholesterolemia and dyslipidemia treatment. Many of their clinical effects, however, are still enigmatic. This article describes how a side road of the mevalonate pathway, characterized in recent years, can rationalize a major fraction of these unexplained observations. This side road is the enzymatic isopentenylation of selenocysteine-tRNA([Ser]Sec) (Sec-tRNA), the singular tRNA to decode the unusual amino acid selenocysteine. The functionally indispensable isopentenylation of Sec-tRNA requires a unique interm…

chemistry.chemical_classificationSelenocysteineCoenzyme AHypercholesterolemiaPeroxisome Proliferator-Activated ReceptorsIsopentenyl pyrophosphateMevalonic AcidProteinsBiologyPeroxisomeRNA Transfer Amino AcylAmino acidchemistry.chemical_compoundEnzymechemistryBiochemistryAnimalsMevalonate pathwaySelenoproteinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineSelenoproteinsTrends in cardiovascular medicine
researchProduct

Combined sub-optimal doses of Rosuvastatin and Bexarotene impairs angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox…

2015

Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis. Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment. Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 μM), or a combination of both were administered to human umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 μM Ang-II (4 h). Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 μM), which did n…

medicine.medical_specialtyTetrahydronaphthalenesPhysiologyPeroxisome Proliferator-Activated ReceptorsClinical BiochemistryCCL2BiologyNitric OxideBiochemistryPeripheral blood mononuclear cellCell LineInternal medicineCell AdhesionmedicineAnticarcinogenic AgentsHumansRosuvastatinInterleukin 8Rosuvastatin CalciumMolecular BiologyGeneral Environmental ScienceSistema cardiovascularBexaroteneSulfonamidesDiabetisArtèriesAngiotensin IIMembrane ProteinsNADPH OxidasesArteriesCell BiologyAngiotensin IIFluorobenzenesCXCL1Original Research CommunicationsPyrimidinesRetinoid X ReceptorsEndocrinologyNADPH Oxidase 5BexaroteneLeukocytes MononuclearGeneral Earth and Planetary SciencesSignal transductionSignal Transductionmedicine.drug
researchProduct

Peroxisome Proliferator-Activated Receptors and Atherosclerosis

2011

The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPARα, -γ, and -δ/β, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, …

peroxisome proliferator-activated receptors gammaPeroxisome proliferator-activated receptor gammamedicine.medical_specialtyPeroxisome Proliferator-Activated Receptorsperoxisome proliferator-activated receptors alphaInflammationatherosclerotic plaque030204 cardiovascular system & hematology03 medical and health sciencesatherosclerosi0302 clinical medicineInternal medicineHumansMedicineReceptorHypolipidemic Agents030304 developmental biology0303 health sciencesbusiness.industryFibric Acidsperoxisome proliferator-activated receptors γLipid metabolismPeroxisomeAtherosclerosisLipid Metabolismperoxisome proliferator-activated receptors α3. Good healthEndocrinologyNuclear receptorCancer researchlipids (amino acids peptides and proteins)Peroxisome proliferator-activated receptor alphaatherosclerosismedicine.symptomSignal transductionCardiology and Cardiovascular MedicinebusinessSignal TransductionAngiology
researchProduct